-
DJ
Slamon,
B
Leyland-Jones,
S
Shak
(2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
N Engl J Med, 344
-
M.
Rimawi,
I.
Mayer,
A.
Forero,
R.
Nanda,
M.
Goetz,
Angel
Rodriguez,
A.
Pavlick,
Tao
Wang,
S.
Hilsenbeck,
C.
Gutierrez,
R.
Schiff,
C.
Osborne,
Jenny
Chang
(2013)
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 14
-
M.
Coombes,
Emma
Ph.D.,
Lorna
Ph.D.,
Robert
M.Phil.,
Ph.D
Jassem,
Thierry
Ph.D.,
Stephen
M.D.,
Isabel
M.D.,
M.
Bertelli,
Olaf
M.D.,
Alan
Ph.D.,
Emilio
M.D.,
David
M.D.,
M.
Coleman,
Lesley
M.D.,
D.Phil,
M.
Mickiewicz,
D.M.Sc
Andersen,
Per
Lønning,
Giorgio
Ph.D.,
Alan
Ph.D.,
Nick
M.D.,
M.Sc
Snowdon,
Ph.D
Carpentieri,
M.
Massimini,
M.Sc
Bliss
(1977)
THE NEW ENGLAND JOURNAL OF MEDICINE
The Lancet, 309
-
Mark
Barok,
M.
Tanner,
Katri
Köninki,
J.
Isola
(2011)
Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo
Breast Cancer Research : BCR, 13
-
M.
Rimawi,
J.
Ferrero,
J.
Haba-Rodríguez,
C.
Poole,
S.
Placido,
C.
Osborne,
R.
Hegg,
V.
Easton,
Christine
Wohlfarth,
G.
Arpino
(2018)
First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 28
-
Xu
Bh,
Q.
Ouyang,
Wei
Li,
Zefei
Jiang,
Z.
Tong,
Yunjiang
Liu,
Hongyu
Li,
Shiying
Yu,
Jifeng
Feng,
Shu
Wang,
X.
Hu,
X.
Zhu,
J.
Zou
(2018)
Abstract PD3-08: A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab
Cancer Research, 78
-
R.
Nahta,
L.
Yuan,
Bing
Zhang,
R.
Kobayashi,
F.
Esteva
(2005)
Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.
Cancer research, 65 23
-
Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: results from the PANACEA
-
J.
Nordstrom,
S.
Gorlatov,
Wenjun
Zhang,
Yinhua
Yang,
Ling
Huang,
S.
Burke,
Hua
Li,
V.
Ciccarone,
Tengfei
Zhang,
J.
Stavenhagen,
S.
Koenig,
S.
Stewart,
P.
Moore,
S.
Johnson,
E.
Bonvini
(2011)
Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties
Breast Cancer Research : BCR, 13
-
K.
Blackwell,
H.
Burstein,
A.
Storniolo,
H.
Rugo,
G.
Sledge,
G.
Aktan,
C.
Ellis,
A.
Florance,
S.
Vukelja,
J.
Bischoff,
J.
Baselga,
J.
O’Shaughnessy
(2012)
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 21
-
(2016)
SYD985, a novel anti-HER2 ADC, shows promising activity in patients with HER2-positive and HER2-negative metastatic breast cancer [abstract
-
A.
Witkiewicz,
Derek
Cox,
E.
Knudsen
(2014)
CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models
Genes & Cancer, 5
-
E.
Hamilton,
V.
Borges,
A.
Conlin,
L.
Walker,
S.
Moulder
(2017)
Abstract P4-21-01: Efficacy results of a phase 1b study of ONT-380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases (mets)
Cancer Research, 77
-
P.
Nuciforo,
S.
Thyparambil,
C.
Aura,
A.
Garrido-Castro,
M.
Vilaró,
V.
Peg,
J.
Jimenez,
Rocio
Vicario,
F.
Cecchi,
W.
Hoos,
J.
Burrows,
T.
Hembrough,
J.
Ferreres,
J.
Peréz-García,
J.
Arribas,
J.
Cortés,
M.
Scaltriti
(2015)
High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti‐HER2 therapy
Molecular Oncology, 10
-
Phase I doseescalation trial of ONT-380 in combination with trastuzumab in patients (pts) with HER2+ breast cancer brain metastases
-
A.
DeMichele,
A.
Clark,
K.
Tan,
D.
Heitjan,
Kristi
Gramlich,
M.
Gallagher,
P.
Lal,
M.
Feldman,
Paul
Zhang,
Christopher
Colameco,
D.
Lewis,
Melissa
Langer,
N.
Goodman,
S.
Domchek,
K.
Gogineni,
M.
Rosen,
K.
Fox,
P.
O'dwyer
(2014)
CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
Clinical Cancer Research, 21
-
(2017)
Abemaciclib for the treatment of brain metastases secondary to hormone receptor positive breast cancer [abstract
-
F.
André,
S.
Hurvitz,
A.
Fasolo,
L.
Tseng,
G.
Jerusalem,
S.
Wilks,
R.
O'Regan,
C.
Isaacs,
M.
Toi,
H.
Burris,
Wei
He,
D.
Robinson,
Markus
Riester,
T.
Taran,
David
Chen,
D.
Slamon
(2016)
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 18
-
Sarika
Jain,
Ami
Shah,
C.
Santa-Maria,
K.
Siziopikou,
A.
Rademaker,
I.
Helenowski,
M.
Cristofanilli,
W.
Gradishar
(2018)
Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy
Breast Cancer Research and Treatment, 171
-
Results from KATE2, a randomized phase 2 study of atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1
-
M.
Alsina,
V.
Boni,
J.
Schellens,
V.
Moreno,
K.
Bol,
M.
Westendorp,
L.
Sirulnik,
J.
Tabernero,
E.
Calvo
(2017)
First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC).
Journal of Clinical Oncology, 35
-
M.
Scaltriti,
F.
Rojo,
A.
Ocaña,
J.
Anido,
M.
Guzman,
J.
Cortés,
S.
Cosimo,
X.
Matías-Guiu,
S.
Cajal,
J.
Arribas,
J.
Baselga
(2007)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
Journal of the National Cancer Institute, 99 8
-
Carla
Ríos-Luci,
Sara
García-Alonso,
E.
Dı́az-Rodrı́guez,
Mercedes
Nadal-Serrano,
J.
Arribas,
A.
Ocaña,
A.
Pandiella
(2017)
Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity.
Cancer research, 77 17
-
S.
Hurvitz,
F.
André,
Zefei
Jiang,
Z.
Shao,
M.
Mano,
S.
Neciosup,
L.
Tseng,
Qingyuan
Zhang,
K.
Shen,
Donggeng
Liu,
L.
Dreosti,
H.
Burris,
M.
Toi,
M.
Buyse,
David
Cabaribere,
M.
Lindsay,
S.
Rao,
L.
Pacaud,
T.
Taran,
D.
Slamon
(2015)
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
The Lancet. Oncology, 16 7
-
N.
Lin
(2015)
Better treatments needed for breast cancer brain metastases.
The Lancet. Oncology, 16 16
-
R.
Finn,
J.
Dering,
D.
Conklin,
O.
Kalous,
David
Cohen,
Amrita
Desai,
C.
Ginther,
M.
Atefi,
I.
Chen,
C.
Fowst,
G.
Los,
D.
Slamon
(2009)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Breast Cancer Research : BCR, 11
-
Y.
Choi,
Xiao-yu
Li,
P.
Hydbring,
Takaomi
Sanda,
Takaomi
Sanda,
Joanna
Stefano,
A.
Christie,
Sabina
Signoretti,
Sabina
Signoretti,
A.
Look,
A.
Look,
Andrew
Kung,
Harald
Boehmer,
P.
Sicinski
(2012)
The requirement for cyclin D function in tumor maintenance.
Cancer cell, 22 4
-
F.
Ma,
Qiao
Li,
Shan-shan
Chen,
Wenjie
Zhu,
Ying
Fan,
Jiayu
Wang,
Yang
Luo,
P.
Xing,
B.
Lan,
Meiying
Li,
Z.
Yi,
R.
Cai,
P.
Yuan,
Pin
Zhang,
Qing
Li,
Bing-he
Xu
(2017)
Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 27
-
M.
Rimawi,
R.
Schiff,
C.
Osborne
(2015)
Targeting HER2 for the treatment of breast cancer.
Annual review of medicine, 66
-
M.
Wermke,
J.
Alt,
J.
Kauh,
J.
Back,
Y.
Salhi,
V.
Reddy,
E.
Bayever,
S.
Ochsenreither
(2018)
Preliminary biomarker and pharmacodynamic data from a phase I study of single-agent bispecific antibody T-cell engager GBR 1302 in subjects with HER2-positive cancers.
Journal of Clinical Oncology, 36
-
C.
Saura,
F.
Thistlethwaite,
U.
Banerji,
S.
Lord,
V.
Moreno,
I.
Macpherson,
V.
Boni,
C.
Rolfo,
E.
Vries,
C.
Herpen,
S.
Rottey,
J.
Geenen,
F.
Eskens,
M.
Martín,
E.
Mommers,
N.
Koper,
Roel
Mulder,
P.
Aftimos
(2018)
A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer.
Journal of Clinical Oncology, 36
-
RA
Freedman,
RS
Gelman,
M
Melisko
(2017)
TBCRC 022: phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM) [abstract]
J Clin Oncol, 35
-
J.
Cortés,
V.
Diéras,
J.
Ro,
J.
Barrière,
T.
Bachelot,
S.
Hurvitz,
É.
Rhun,
M.
Espié,
Sung-Bae
Kim,
A.
Schneeweiss,
J.
Sohn,
J.
Nabholtz,
P.
Kellokumpu-Lehtinen,
J.
Taguchi,
F.
Piacentini,
E.
Ciruelos,
P.
Bono,
M.
Ould-Kaci,
Flavien
Roux,
H.
Joensuu
(2015)
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
The Lancet. Oncology, 16 16
-
CM
van Herpen,
U
Banerji,
EC
Mommers
(2015)
Phase I dose-escalation trial with the DNA-alkylating anti-HER2 antibody-drug conjugate SYD985 [abstract]
Eur J Cancer, 51
-
R.
Freedman,
R.
Gelman,
J.
Wefel,
I.
Krop,
M.
Melisko,
A.
Lowe,
N.
Agar,
K.
Blackwell,
R.
Connolly,
P.
Niravath,
C.
Poznak,
S.
Puhalla,
N.
Ryabin,
E.
Lawler,
N.
Ibrahim,
Minetta
Liu,
A.
Wolff,
E.
Winer,
N.
Lin
(2014)
TBCRC 022: Phase II trial of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM).
Journal of Clinical Oncology, 32
-
V.
Borges,
C.
Ferrario,
N.
Aucoin,
C.
Falkson,
Q.
Khan,
I.
Krop,
S.
Welch,
A.
Conlin,
J.
Chaves,
Philippe
Bédard,
M.
Chamberlain,
T.
Gray,
A.
Vo,
E.
Hamilton
(2018)
Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial
JAMA Oncology, 4
-
A.
Musolino,
N.
Naldi,
B.
Bortesi,
D.
Pezzuolo,
M.
Capelletti,
G.
Missale,
D.
Laccabue,
A.
Zerbini,
R.
Camisa,
G.
Bisagni,
T.
Neri,
A.
Ardizzoni
(2008)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 11
-
L.
Dirix,
I.
Takács,
G.
Jerusalem,
P.
Nikolinakos,
H.
Arkenau,
A.
Forero-Torres,
R.
Boccia,
M.
Lippman,
R.
Somer,
M.
Šmakal,
L.
Emens,
B.
Hrinczenko,
W.
Edenfield,
J.
Gurtler,
A.
Heydebreck,
H.
Grote,
K.
Chin,
E.
Hamilton
(2017)
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Breast Cancer Research and Treatment, 167
-
Non-clinical pharmacokinetics of XMT-1522, a HER2 targeting auristatin-based antibody
-
Lucía
Gandullo-Sánchez,
E.
Capone,
A.
Ocaña,
S.
Iacobelli,
G.
Sala,
A.
Pandiella
(2020)
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
EMBO Molecular Medicine, 12
-
G.
Bianchini,
L.
Gianni
(2014)
The immune system and response to HER2-targeted treatment in breast cancer.
The Lancet. Oncology, 15 2
-
R.
Freedman,
R.
Gelman,
J.
Wefel,
M.
Melisko,
K.
Hess,
R.
Connolly,
C.
Poznak,
P.
Niravath,
S.
Puhalla,
N.
Ibrahim,
K.
Blackwell,
B.
Moy,
C.
Herold,
Minetta
Liu,
A.
Lowe,
N.
Agar,
N.
Ryabin,
Sarah
Farooq,
E.
Lawler,
M.
Rimawi,
I.
Krop,
A.
Wolff,
E.
Winer,
N.
Lin
(2016)
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 9
-
J.
Stagg,
S.
Loi,
U.
Divisekera,
S.
Ngiow,
Hélène
Duret,
H.
Yagita,
M.
Teng,
M.
Smyth
(2011)
Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy
Proceedings of the National Academy of Sciences, 108
-
D.
Slamon,
G.
Clark,
S.
Wong,
W.
Levin,
A.
Ullrich,
W.
McGuire
(1987)
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
Science, 235 4785
-
N.
Keegan,
J.
Walshe,
S.
Toomey,
G.
Gullo,
M.
Kennedy,
K.
Bulger,
J.
McCaffrey,
C.
Kelly,
J.
Crown,
K.
Egan,
J.
Kerr,
A.
Teiserskiene,
A.
Hernando,
I.
Parker,
R.
McDermott,
M.
Keane,
W.
Grogan,
O.
Breathnach,
P.
Morris,
B.
Hennessy
(2018)
A phase Ib trial of copanlisib and tratuzumab in pretreated recurrent or metastatic HER2-positive breast cancer “PantHER”.
Journal of Clinical Oncology, 36
-
Yoichi
Nagata,
K.
Lan,
Xiaoyan
Zhou,
M.
Tan,
F.
Esteva,
A.
Sahin,
K.
Klos,
Ping
Li,
B.
Monia,
Nina
Nguyen,
G.
Hortobagyi,
M.
Hung,
Dihua
Yu
(2004)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.
Cancer cell, 6 2
-
I.
Krop,
Sung-Bae
Kim,
Antonio
Martín,
P.
LoRusso,
J.
Ferrero,
T.
Badovinac-Črnjević,
S.
Hoersch,
M.
Smitt,
H.
Wildiers
(2017)
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
The Lancet. Oncology, 18 6
-
K.
Berns,
H.
Horlings,
B.
Hennessy,
M.
Madiredjo,
E.
Hijmans,
K.
Beelen,
S.
Linn,
A.
González-Angulo,
K.
Stemke‐Hale,
M.
Hauptmann,
R.
Beijersbergen,
G.
Mills,
M.
Vijver,
R.
Bernards
(2007)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
Cancer cell, 12 4
-
B.
Kaufman,
J.
Mackey,
M.
Clemens,
P.
Bapsy,
A.
Vaid,
A.
Wardley,
S.
Tjulandin,
M.
Jahn,
M.
Lehle,
A.
Feyereislova,
C.
Révil,
A.
Jones
(2009)
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 33
-
MohammadA
Sabbaghi,
G.
Gil-Gómez,
Cristina
Guardia,
S.
Servitja,
O.
Arpí,
Sara
García-Alonso,
S.
Menéndez,
M.
Arumí-Uría,
L.
Serrano,
M.
Salido,
A.
Muntasell,
M.
Martínez-García,
S.
Zazo,
C.
Chamizo,
P.
González-Alonso,
J.
Madoz-Gúrpide,
P.
Eroles,
J.
Arribas,
I.
Tusquets,
A.
Lluch,
A.
Pandiella,
F.
Rojo,
A.
Rovira,
J.
Albanell
(2017)
Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer
Clinical Cancer Research, 23
-
A.
Llombart-Cussac,
J.
Cortés,
L.
Paré,
P.
Galván,
B.
Bermejo,
N.
Martínez,
M.
Vidal,
S.
Pernas,
R.
López,
M.
Muñoz,
P.
Nuciforo,
S.
Morales,
Mafalda
Oliveira,
L.
Peña,
A.
Peláez,
A.
Prat
(2017)
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
The Lancet. Oncology, 18 4
-
L.
Carey,
D.
Berry,
C.
Cirrincione,
W.
Barry,
B.
Pitcher,
L.
Harris,
D.
Ollila,
I.
Krop,
N.
Henry,
D.
Weckstein,
C.
Anders,
Baljit
Singh,
K.
Hoadley,
M.
Iglesia,
M.
Cheang,
C.
Perou,
E.
Winer,
C.
Hudis
(2016)
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 6
-
Ahrong
Kim,
So
Lee,
Y.
Kim,
W.
Park,
D.
Park,
J.
Kim,
C.
Lee,
G.
Gong,
G.
Huh,
K.
Choi
(2017)
Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value
Scientific Reports, 7
-
J.
Diehl,
M.
Cheng,
M.
Roussel,
C.
Sherr
(1998)
Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization.
Genes & development, 12 22
-
A
Yurkovetskiy,
D
Gumerov,
E
Ter-Ovanesyan
(2017)
Non-clinical pharmacokinetics of XMT-1522, a HER2 targeting auristatin-based antibody drug conjugate [abstract]
Proc Am Assoc Cancer Res, 58
-
Cristina
Torres,
Mary
Wu,
S.
Hobor,
Elanor
Wainwright,
Matthew
Martin,
H.
Patel,
W.
Grey,
E.
Grönroos,
Steven
Howell,
J.
Carvalho,
A.
Snijders,
M.
Bustin,
D.
Bonnet,
Paul
Smith,
C.
Swanton,
M.
Howell,
Paola
Scaffidi
(2020)
Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis
Nature Communications, 11
-
Marlon
Hinner,
R.
Aiba,
A.
Wiedenmann,
C.
Schlosser,
Andrea
Allersdorfer,
G.
Matschiner,
C.
Rothe,
U.
Moebius,
H.
Kohrt,
S.
Olwill
(2015)
Costimulatory T cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein
Journal for Immunotherapy of Cancer, 3
-
S.
Chandarlapaty,
R.
Sakr,
D.
Giri,
S.
Patil,
A.
Heguy,
M.
Morrow,
S.
Modi,
L.
Norton,
N.
Rosen,
C.
Hudis,
T.
King
(2012)
Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer
Clinical Cancer Research, 18
-
F.
André,
R.
O'Regan,
M.
Ozguroglu,
M.
Toi,
Bing-he
Xu,
G.
Jerusalem,
N.
Masuda,
S.
Wilks,
F.
Arena,
C.
Isaacs,
Y.
Yap,
Z.
Pápai,
I.
Láng,
A.
Armstrong,
G.
Lerzo,
M.
White,
K.
Shen,
J.
Litton,
David
Chen,
Yufen
Zhang,
S.
Ali,
T.
Taran,
L.
Gianni
(2014)
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.
The Lancet. Oncology, 15 6
-
X.
Pivot,
A.
Manikhas,
B.
Żurawski,
E.
Chmielowska,
B.
Karaszewska,
R.
Allerton,
S.
Chan,
A.
Fabi,
P.
Bidoli,
S.
Gori,
E.
Ciruelos,
M.
Dank,
L.
Hornyák,
S.
Margolin,
A.
Nusch,
R.
Parikh,
F.
Nagi,
M.
Desilvio,
S.
Santillana,
R.
Swaby,
V.
Semiglazov
(2015)
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 14
-
MJ
Hinner,
R
Bel Aiba,
A
Wiedenmann
(2015)
Costimulatory T cell engagement via a novel bispecific anti-CD137/anti-HER2 protein [abstract]
J Immunother Cancer, 3
-
A.
Fernández,
M.
Borrego,
M.
Martin,
S.
Antolín,
M.
Atienza,
Á.
Montaño,
N.
Ribelles,
Á.
Guerrero,
M.
Muñoz,
I.
Fernández-Pérez,
A.
Urruticoechea,
A.
Gonzalez,
S.
Simón,
J.
Varela,
M.
Escudero,
S.
Benito,
R.
Caballero,
E.
Carrasco,
F.
Rojo,
A.
Pandiella
(2017)
239PDA phase II trial of dasatinib (D) in combination with trastuzumab (T) and paclitaxel (P) in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients (pts): GEICAM/2010-04
Annals of Oncology, 28
-
T.
Doi,
K.
Shitara,
Y.
Naito,
A.
Shimomura,
Y.
Fujiwara,
K.
Yonemori,
C.
Shimizu,
T.
Shimoi,
Y.
Kuboki,
N.
Matsubara,
A.
Kitano,
Takahiro
Jikoh,
Caleb
Lee,
Y.
Fujisaki,
Y.
Ogitani,
A.
Yver,
K.
Tamura
(2017)
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
The Lancet. Oncology, 18 11
-
M.
Pegram,
E.
Hamilton,
A.
Tan,
A.
Storniolo,
N.
Elgeioushi,
S.
Marshall,
S.
Abdullah,
M.
Patel
(2018)
Phase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer
Annals of Oncology, 29
-
T.
Abair,
S.
Peck,
J.
O’Shaughnessy
(2011)
The San Antonio Breast Cancer Symposium
Clinical Breast Cancer, 11
-
I.
Gingras,
G.
Gebhart,
E.
Azambuja,
M.
Piccart-Gebhart
(2017)
HER2-positive breast cancer is lost in translation: time for patient-centered research
Nature Reviews Clinical Oncology, 14
-
P.
Trail,
G.
Dubowchik,
T.
Lowinger
(2018)
Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design.
Pharmacology & therapeutics, 181
-
A.
Ocaña,
M.
Gil-Martin,
Miguel
Martín,
F.
Rojo,
S.
Antolín,
Á.
Guerrero,
J.
Trigo,
M.
Muñoz,
A.
Pandiella,
Núria
Diego,
S.
Bezares,
R.
Caballero,
E.
Carrasco,
A.
Urruticoechea
(2017)
A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study
Oncotarget, 8
-
N.
Harbeck,
Chiun-Sheng
Huang,
S.
Hurvitz,
D.
Yeh,
Z.
Shao,
S.
Im,
K.
Jung,
K.
Shen,
J.
Ro,
J.
Jassem,
Qingyuan
Zhang,
Y.
Im,
M.
Wojtukiewicz,
Q.
Sun,
Shin-Cheh
Chen,
R.
Goeldner,
M.
Uttenreuther-Fischer,
Bing-he
Xu,
M.
Piccart-Gebhart
(2016)
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
The Lancet. Oncology, 17 3
-
F.
Meric-Bernstam,
M.
Beeram,
J.
Mayordomo,
D.
Hanna,
J.
Ajani,
M.
Murphy,
R.
Murthy,
S.
Piha-Paul,
T.
Bauer,
J.
Bendell,
A.
El-Khoueiry,
H.
Lenz,
M.
Press,
Nels
Royer,
D.
Hausman,
E.
Hamilton
(2018)
Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers.
Journal of Clinical Oncology, 36
-
S.
Goel,
Qi
Wang,
April
Watt,
S.
Tolaney,
D.
Dillon,
Wei
Li,
S.
Ramm,
S.
Ramm,
A.
Palmer,
A.
Palmer,
Haluk
Yuzugullu,
V.
Varadan,
D.
Tuck,
L.
Harris,
Kwok-kin
Wong,
X.
Liu,
P.
Sicinski,
E.
Winer,
I.
Krop,
Jean
Zhao,
Jean
Zhao
(2016)
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.
Cancer cell, 29 3
-
V.
Serra,
M.
Scaltriti,
L.
Prudkin,
P.
Eichhorn,
Y.
Ibrahim,
S.
Chandarlapaty,
Benjamin
Markman,
Olga
Rodríguez,
M.
Guzmán,
Sonia
Rodriguez,
M.
Gili,
M.
Russillo,
J.
Parra,
Sharat
Singh,
J.
Arribas,
N.
Rosen,
J.
Baselga
(2011)
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
Oncogene, 30
-
K.
Gelmon,
F.
Boyle,
B.
Kaufman,
D.
Huntsman,
A.
Manikhas,
A.
Leo,
Miguel
Martín,
L.
Schwartzberg,
J.
Lemieux,
S.
Aparicio,
L.
Shepherd,
S.
Dent,
S.
Ellard,
K.
Tonkin,
K.
Pritchard,
T.
Whelan,
D.
Nomikos,
A.
Nusch,
R.
Coleman,
H.
Mukai,
S.
Tjulandin,
R.
Khasanov,
S.
Rizel,
Anne
Connor,
S.
Santillana,
J.
Chapman,
W.
Parulekar
(2015)
Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 14
-
F.
Zammarchi,
S.
Chivers,
David
Williams,
Lauren
Adams,
Maria
Mellinas-Gomez,
P.
Tyrer,
Simon
Corbett,
François
D'Hooge,
Sandamali
Dissanayake,
S.
Sims,
K.
Havenith,
P.
Howard,
J.
Hartley,
P.
Berkel
(2016)
ADCT-502, a novel pyrrolobenzodiazepine (PBD)-based antibody-drug conjugate (ADC) targeting low HER2-expressing solid cancers
European Journal of Cancer, 69
-
John
Li,
Samuel
Perry,
Vanessa
Muniz-Medina,
X.
Wang,
Leslie
Wetzel,
M.
Rebelatto,
M.
Hinrichs,
Binyam
Bezabeh,
R.
Fleming,
N.
Dimasi,
H.
Feng,
D.
Toader,
A.
Yuan,
Lan
Xu,
Jia
Lin,
Changshou
Gao,
Herren
Wu,
R.
Dixit,
J.
Osbourn,
S.
Coats
(2016)
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy.
Cancer cell, 29 1
-
A.
Awada,
R.
Colomer,
Kenichi
Inoue,
I.
Bondarenko,
R.
Badwe,
G.
Demetriou,
Soo-Chin
Lee,
A.
Mehta,
Sung-Bae
Kim,
T.
Bachelot,
C.
Goswami,
S.
Deo,
R.
Bose,
A.
Wong,
Feng
Xu,
B.
Yao,
R.
Bryce,
L.
Carey
(2016)
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.
JAMA oncology, 2 12
-
Irene
Ruiz,
Rocio
Vicario,
B.
Morancho,
C.
Morales,
E.
Arenas,
S.
Herter,
A.
Freimoser-Grundschober,
Jitka
Somandin,
J.
Sam,
O.
Ast,
Águeda
Barriocanal,
Antonio
Luque,
Marta
Escorihuela,
I.
Varela,
I.
Cuartas,
P.
Nuciforo,
R.
Fasani,
V.
Peg,
I.
Rubio,
J.
Cortés,
V.
Serra,
S.
Escrivá-de-Romaní,
J.
Sperinde,
A.
Chenna,
Weidong
Huang,
J.
Winslow,
J.
Albanell,
J.
Seoane,
M.
Scaltriti,
J.
Baselga,
J.
Tabernero,
P.
Umaña,
M.
Bacac,
C.
Saura,
C.
Klein,
J.
Arribas
(2018)
p95HER2–T cell bispecific antibody for breast cancer treatment
Science Translational Medicine, 10
-
J.
Baselga,
J.
Cortés,
S.
Im,
E.
Clark,
G.
Ross,
A.
Kiermaier,
S.
Swain
(2014)
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 33
-
S.
Luen,
R.
Salgado,
S.
Fox,
P.
Savas,
J.
Eng-Wong,
E.
Clark,
A.
Kiermaier,
S.
Swain,
J.
Baselga,
S.
Michiels,
S.
Loi
(2017)
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
The Lancet. Oncology, 18 1
-
PAM50 intrinsic subtype predicts survival outcome in HER2-positive/hormone receptor-positive metastatic breast cancer treated with palbociclib and trastuzumab: a correlative analysis of the PATRICIA
-
Yeon-Hee
Park,
Kyung-Hun
Lee,
J.
Sohn,
K.
Lee,
K.
Jung,
J.
Kim,
K.
Lee,
J.
Ahn,
Tae-Yong
Kim,
G.
Kim,
I.
Park,
Sung-Bae
Kim,
Se
Kim,
H.
Han,
Y.
Im,
J.
Ahn,
Jung-Yong
Kim,
Jahoon
Kang,
S.
Im
(2018)
A phase II trial of the pan‐HER inhibitor poziotinib, in patients with HER2‐positive metastatic breast cancer who had received at least two prior HER2‐directed regimens: results of the NOV120101‐203 trial
International Journal of Cancer, 143
-
G.
Gebhart,
L.
Lamberts,
Z.
Wimana,
C.
Garcia,
P.
Emonts,
L.
Ameye,
S.
Stroobants,
M.
Huizing,
P.
Aftimos,
J.
Tol,
W.
Oyen,
D.
Vugts,
O.
Hoekstra,
C.
Schröder,
Catharina
van,
Oordt,
T.
Guiot,
A.
Brouwers,
A.
Awada,
E.
Vries,
P.
Flamen
(2016)
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.
Annals of oncology : official journal of the European Society for Medical Oncology, 27 4
-
R.
D’Amico,
Deepak
Khatri,
Noah
Reichman,
Nitesh
Patel,
Tamika
Wong,
S.
Fralin,
Mona
Li,
Jason
Ellis,
Rafael
Ortiz,
D.
Langer,
J.
Boockvar
(2020)
Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood–brain barrier disruption: where are we now, and where we are going
Journal of Neuro-Oncology, 147
-
E.
Mittendorf,
G.
Clifton,
J.
Holmes,
E.
Schneble,
D.
Echo,
S.
Ponniah,
G.
Peoples
(2014)
Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology, 25 9
-
Min-feng
Liu,
Can
Luo,
Jianyu
Dong,
Jingyun
Guo,
Qing
Luo,
Changsheng
Ye,
Zhaoze
Guo
(2020)
CircRNA_103809 Suppresses the Proliferation and Metastasis of Breast Cancer Cells by Sponging MicroRNA-532-3p (miR-532-3p)
Frontiers in Genetics, 11
-
Wen
Jian,
Chun-Mei
Wei,
Jia-Hui
Guan,
Changhua
Mo,
Yu-Tao
Xu,
Wen-Bo
Zheng,
Lang
Li,
Chun
Gui
(2020)
Association between serum HER2/ErbB2 levels and coronary artery disease: a case–control study
Journal of Translational Medicine, 18
-
S.
Johnston,
J.
Pippen,
X.
Pivot,
M.
Lichinitser,
S.
Sadeghi,
V.
Diéras,
H.
Gómez,
G.
Romieu,
A.
Manikhas,
M.
Kennedy,
M.
Press,
J.
Maltzman,
A.
Florance,
L.
O’Rourke,
C.
Oliva,
S.
Stein,
M.
Pegram
(2009)
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 33
-
Gail
Phillips,
Guangmin
Li,
D.
Dugger,
Lisa
Crocker,
Kathryn
Parsons,
Elaine
Mai,
W.
Blättler,
J.
Lambert,
R.
Chari,
R.
Lutz,
W.
Wong,
Frederic
Jacobson,
H.
Koeppen,
R.
Schwall,
S.
Kenkare-Mitra,
S.
Spencer,
M.
Sliwkowski
(2008)
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.
Cancer research, 68 22
-
A.
Patnaik,
L.
Rosen,
S.
Tolaney,
A.
Tolcher,
J.
Goldman,
L.
Gandhi,
K.
Papadopoulos,
M.
Beeram,
D.
Rasco,
J.
Hilton,
A.
Nasir,
R.
Beckmann,
A.
Schade,
Angie
Fulford,
Tuan
Nguyen,
R.
Martinez,
P.
Kulanthaivel,
Lily
Li,
Martin
Frenzel,
D.
Cronier,
E.
Chan,
K.
Flaherty,
P.
Wen,
G.
Shapiro
(2016)
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
Cancer discovery, 6 7
-
Guangmin
Li,
Jun
Guo,
Ben-Quan
Shen,
D.
Yadav,
M.
Sliwkowski,
Lisa
Crocker,
J.
Lacap,
G.
Phillips
(2018)
Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells
Molecular Cancer Therapeutics, 17
-
S.
Verma,
D.
Miles,
L.
Gianni,
I.
Krop,
M.
Welslau,
J.
Baselga,
M.
Pegram,
D.
Oh,
V.
Diéras,
E.
Guardino,
L.
Fang,
Michael
Lu,
S.
Olsen,
K.
Blackwell
(2012)
Trastuzumab emtansine for HER2-positive advanced breast cancer.
The New England journal of medicine, 367 19
-
Qunyan
Yu,
Y.
Geng,
P.
Sicinski
(2001)
Specific protection against breast cancers by cyclin D1 ablation
Nature, 411
-
Y.
Bang,
G.
Giaccone,
S.
Im,
D.
Oh,
T.
Bauer,
J.
Nordstrom,
H.
Li,
G.
Chichili,
P.
Moore,
S.
Hong,
S.
Stewart,
J.
Baughman,
R.
Lechleider,
H.
Burris
(2017)
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors
Annals of Oncology, 28
-
H.
Iwata,
K.
Tamura,
T.
Doi,
J.
Tsurutani,
S.
Modi,
Haeseong
Park,
I.
Krop,
Y.
Sagara,
C.
Redfern,
R.
Murthy,
R.
Redman,
K.
Shitara,
Y.
Fujisaki,
M.
Sugihara,
Lin
Zhang,
J.
Shahidi,
A.
Yver,
S.
Takahashi
(2018)
Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.
Journal of Clinical Oncology, 36
-
C.
Herpen,
U.
Banerji,
E.
Mommers,
N.
Koper,
P.
Goedings,
J.
Lopez,
A.
Awada,
H.
Fiebrich,
P.
Aftimos
(2015)
333 Phase I dose-escalation trial with the DNA-alkylating anti-HER2 antibody-drug conjugate SYD985
European Journal of Cancer, 51
-
Siyuan
Zhang,
Wen-Chien
Huang,
Ping
Li,
Hua
Guo,
Say-Bee
Poh,
Samuel
Brady,
Y.
Xiong,
L.
Tseng,
Shau-Hsuan
Li,
Zhaoxi
Ding,
A.
Sahin,
F.
Esteva,
G.
Hortobagyi,
Dihua
Yu
(2011)
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
Nature Medicine, 17
-
Charles
Geyer,
J.
Forster,
D.
Lindquist,
Stephen
Chan,
C.
Romieu,
T.
Pieńkowski,
A.
Jagiełło-Gruszfeld,
J.
Crown,
Arlene
Chan,
Bella
Kaufman,
Dimosthenis
Skarlos,
M.
Campone,
Neville
Davidson,
Mark
Berger,
C.
Oliva,
S.
Rubin,
S.
Stein,
David
Cameron
(2006)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
The New England journal of medicine, 355 26
-
P.
Shah,
S.
Chandarlapaty,
M.
Dickler,
G.
Ulaner,
S.
Zamora,
Valentina
Sterlin,
A.
Iasonos,
C.
Coughlin,
A.
Morozov,
J.
Ero,
N.
Rosen,
T.
Gilewski,
M.
Fornier,
N.
Sklarin,
M.
Berger,
M.
Moynahan,
C.
Hudis,
J.
Baselga,
S.
Modi
(2015)
Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC).
Journal of Clinical Oncology, 33
-
S.
Swain,
J.
Baselga,
Sung-Bae
Kim,
J.
Ro,
V.
Semiglazov,
M.
Campone,
E.
Ciruelos,
J.
Ferrero,
A.
Schneeweiss,
S.
Heeson,
E.
Clark,
G.
Ross,
M.
Benyunes,
J.
Cortés
(2015)
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
The New England journal of medicine, 372 8
-
G.
Minuti,
F.
Cappuzzo,
R.
Duchnowska,
J.
Jassem,
A.
Fabi,
Terence
O'Brien,
A.
Mendoza,
L.
Landi,
W.
Biernat,
B.
Czartoryska-Arłukowicz,
T.
Jankowski,
D.
Zuziak,
J.
Żok,
B.
Szostakiewicz,
M.
Foszczyńska‐Kłoda,
A.
Tempińska-Szałach,
E.
Rossi,
M.
Varella-Garcia
(2012)
Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer
British Journal of Cancer, 107
-
M.
Giuliano,
M.
Giuliano,
Huizhong
Hu,
Yen-chao
Wang,
Xiaoyong
Fu,
A.
Nardone,
S.
Herrera,
Sufeng
Mao,
A.
Contreras,
C.
Gutierrez,
Tao
Wang,
S.
Hilsenbeck,
C.
Angelis,
Nicholas
Wang,
Laura
Heiser,
J.
Gray,
S.
López-Tarruella,
A.
Pavlick,
Meghana
Trivedi,
Meghana
Trivedi,
G.
Chamness,
Jenny
Chang,
C.
Osborne,
M.
Rimawi,
R.
Schiff
(2015)
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy
Clinical Cancer Research, 21
-
J.
Baselga,
Gail
Phillips,
S.
Verma,
J.
Ro,
J.
Huober,
A.
Guardino,
M.
Samant,
S.
Olsen,
S.
Haas,
M.
Pegram
(2016)
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
Clinical Cancer Research, 22
-
Miguel
Martín,
F.
Holmes,
B.
Ejlertsen,
S.
Delaloge,
B.
Moy,
H.
Iwata,
G.
Minckwitz,
S.
Chia,
J.
Mansi,
C.
Barrios,
M.
Gnant,
Z.
Tomašević,
N.
Denduluri,
R.
Šeparović,
E.
Gokmen,
A.
Bashford,
M.
Borrego,
Sung-Bae
Kim,
E.
Jakobsen,
A.
Cicėnienė,
Kenichi
Inoue,
F.
Overkamp,
J.
Heijns,
A.
Armstrong,
J.
Link,
A.
Joy,
R.
Bryce,
A.
Wong,
S.
Moran,
B.
Yao,
Feng
Xu,
A.
Auerbach,
M.
Buyse,
A.
Chan
(2017)
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
The Lancet. Oncology, 18 12